Product Name
SLC19A2, siRNA
Full Product Name
SLC19A2 siRNA (Human)
Product Synonym Names
THT1; TRMA; Thiamine transporter 1; ThTr-1; ThTr1; Solute carrier family 19 member 2; Thiamine carrier 1; TC1
Product Gene Name
SLC19A2 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for O60779
Specificity
SLC19A2 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human SLC19A2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of SLC19A2 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
SLC19A2 sirna
siRNA to inhibit SLC19A2 expression using RNA interference
Applications Tested/Suitable for SLC19A2 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for SLC19A2. It may not necessarily be applicable to this product.
NCBI Accession #
NP_008927.1
[Other Products]
NCBI GenBank Nucleotide #
NM_006996.2
[Other Products]
UniProt Primary Accession #
O60779
[Other Products]
UniProt Secondary Accession #
Q8WV87; Q9UBL7; Q9UKJ2; Q9UN31; Q9UN43; B2R9H0; B4E1X4[Other Products]
UniProt Related Accession #
O60779[Other Products]
Molecular Weight
32,858 Da
NCBI Official Full Name
thiamine transporter 1
NCBI Official Synonym Full Names
solute carrier family 19 (thiamine transporter), member 2
NCBI Official Symbol
SLC19A2 [Similar Products]
NCBI Official Synonym Symbols
TC1; THT1; TRMA; THMD1; THTR1
[Similar Products]
NCBI Protein Information
thiamine transporter 1
UniProt Protein Name
Thiamine transporter 1
UniProt Synonym Protein Names
Solute carrier family 19 member 2; Thiamine carrier 1; TC1
Protein Family
Thiamine transporter
UniProt Gene Name
SLC19A2 [Similar Products]
UniProt Synonym Gene Names
THT1; TRMA; ThTr-1; ThTr1; TC1 [Similar Products]
UniProt Entry Name
S19A2_HUMAN
NCBI Summary for SLC19A2
This gene encodes the thiamin transporter protein. Mutations in this gene cause thiamin-responsive megaloblastic anemia syndrome (TRMA), which is an autosomal recessive disorder characterized by diabetes mellitus, megaloblastic anemia and sensorineural deafness. [provided by RefSeq, Jul 2008]
UniProt Comments for SLC19A2
SLC19A2: High-affinity transporter for the intake of thiamine. Defects in SLC19A2 are the cause of thiamine-responsive megaloblastic anemia syndrome (TRMA); also known as Rogers syndrome. TRMA is an autosomal recessive disease with features that include megaloblastic anemia, mild thrombocytopenia and leucopenia, sensorineural deafness and diabetes mellitus. Belongs to the reduced folate carrier (RFC) transporter (TC 2.A.48) family. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Membrane protein, integral; Transporter, SLC family; Membrane protein, multi-pass; Transporter
Chromosomal Location of Human Ortholog: 1q23.3
Cellular Component: integral to membrane; plasma membrane
Molecular Function: folic acid transporter activity; protein binding; thiamin transmembrane transporter activity; thiamin uptake transmembrane transporter activity
Biological Process: vitamin metabolic process; thiamin and derivative metabolic process; thiamin transport; water-soluble vitamin metabolic process; folic acid transport
Disease: Thiamine-responsive Megaloblastic Anemia Syndrome
Research Articles on SLC19A2
1. The present study confirms the variability of the clinical manifestations caused by the same mutation within patients with TRMA syndrome.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
